financetom
Business
financetom
/
Business
/
Quess Corp to acquire remaining 30% stake in Conneqt from Tata Sons for Rs 208 cr
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Quess Corp to acquire remaining 30% stake in Conneqt from Tata Sons for Rs 208 cr
Apr 16, 2021 2:44 AM

Business services provider Quess Corp on Friday said it will acquire the remaining 30 percent equity stake in Conneqt Business Solutions Ltd from Tata Sons for Rs 208 crore. ”The administration and investment committee has approved the acquisition of 30 percent equity shares in Conneqt Business Solutions Ltd in lieu of Rs 208 crore from Tata Sons Pvt Ltd,” Quess Corp said in a regulatory filing.

With this transaction, Conneqt will become a wholly-owned subsidiary of Quess, the company added. Quess had acquired 51 percent of Conneqt in November 2017, and further increased its stake in Conneqt from 51 percent to 70 percent in May 2019, via infusion of primary capital, which was used to fund the acquisition of Allsec Technologies Ltd.

Quess Corp said this investment will provide Quess full and complete ownership over Conneqt, allowing it to better realise synergies between its various divisions, Conneqt and Allsec. It will also strengthen Quess’ position to accelerate growth in the IT/ITES space, the company said. ”The consolidation of our holding in Conneqt is an affirmation of our continued commitment to Conneqt, its employees and customers.

Also Read

: Expect FY22 to be a good year; ROE should improve to 20% by FY23, says Quess Corp CEO

”This will further accelerate Conneqt’s transition to non-voice services as the business benefits from the triple tailwinds of virtualisation, digitisation, and automation while providing more opportunities to realise synergies with Quess,” said Suraj Moraje, Group CEO and Managing Director of Quess Corp.

First Published:Apr 16, 2021 11:44 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sun Life Announces Leadership Changes for Sun Life Canada
Sun Life Announces Leadership Changes for Sun Life Canada
Sep 11, 2024
08:21 AM EDT, 09/11/2024 (MT Newswires) -- Sun Life (SLF.TO, SLF) on Wednesday said Jacques Goulet has been named executive chair of Sun Life Canada while Jessica Tan succeeds him as president of Sun Life Canada. The two will assume their new positions on September 30. Goulet, who joined Sun Life in 2018, will also continue as the chair of...
Poet Technologies Combines Optical Engine With InSiGa's EML Driver
Poet Technologies Combines Optical Engine With InSiGa's EML Driver
Sep 11, 2024
08:15 AM EDT, 09/11/2024 (MT Newswires) -- Poet Technologies ( POET ) and Chengdu InSiGa Semiconductor Technologies said Wednesday they have developed a solution for 200Gx4 applications using Poet's 200Gx4 transmit optical engine and InSiGa's 200G/lane EML driver ISG-D9616 for 800G and 1.6T modules. The companies will showcase the new product at the China International Optoelectronic Expo until Friday, Poet...
Eupraxia Pharmaceuticals Reports Positive Data from RESOLVE Trial
Eupraxia Pharmaceuticals Reports Positive Data from RESOLVE Trial
Sep 11, 2024
08:15 AM EDT, 09/11/2024 (MT Newswires) -- Eupraxia Pharmaceuticals ( EPRX ) on Wednesday announced additional positive clinical data from its RESOLVE Phase 1b/2a trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis (EoE), an allergic condition that causes the esophagus to be inflamed and not contract properly. The results from the fourth...
BriaCell Reports Positive Data for Bria-IMT in Phase 2 Metastatic Breast Cancer Study - Shares Soar Premarket
BriaCell Reports Positive Data for Bria-IMT in Phase 2 Metastatic Breast Cancer Study - Shares Soar Premarket
Sep 11, 2024
08:19 AM EDT, 09/11/2024 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Wednesday it yielded positive overall survival data in a phase 2 late-stage metastatic breast cancer study evaluating Bria-IMT in combination with an immune check point inhibitor. The 54-patient study showed median survival of 15.6 months in patients treated with Bria-MT compared with 6.7 to 9.3 months for...
Copyright 2023-2026 - www.financetom.com All Rights Reserved